search
Back to results

Effect of Paroxetine on Smokers' Cardiovascular Response to Stress - 1

Primary Purpose

Tobacco Use Disorder

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Paroxetine
Placebo
Sponsored by
University of Minnesota
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Tobacco Use Disorder focused on measuring Smoking

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria: Smokes an average of at least 10 cigarettes per day during the year prior to enrollment Exclusion Criteria: Interested in quitting smoking within the 3 months following enrollment Current unstable medical condition Substance abuse within the year prior to enrollment Current use of any medications (e.g., psychoactive medications, antihypertensives) that, in the opinion of the investigators, might interfere with study measures or that would be expected to interact with paroxetine (e.g., CYP2D6 substrates) Smoking cessation therapy within the 3 months prior to enrollment Regular use of any form of tobacco other than cigarettes Significant psychiatric disorders as assessed by the PRIME-MD and verified by a clinician History of hypersensitivity to any selective serotonin reuptake inhibitor Pregnancy or breastfeeding

Sites / Locations

  • College of Pharmacy

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

1

2

Arm Description

Active medication for 4 weeks followed by placebo for 4 weeks

Placebo for 4 weeks followed by active for 4 weeks

Outcomes

Primary Outcome Measures

Systolic Blood Pressure Response to Stress
Change in systolic blood pressure from Resting period to that observed during a speech delivered immediately after smoking a cigarette

Secondary Outcome Measures

Full Information

First Posted
September 16, 2005
Last Updated
October 30, 2019
Sponsor
University of Minnesota
Collaborators
National Institute on Drug Abuse (NIDA)
search

1. Study Identification

Unique Protocol Identification Number
NCT00218439
Brief Title
Effect of Paroxetine on Smokers' Cardiovascular Response to Stress - 1
Official Title
Smoking, Antidepressants, and Response to Mental Stress
Study Type
Interventional

2. Study Status

Record Verification Date
October 2019
Overall Recruitment Status
Completed
Study Start Date
October 2005 (undefined)
Primary Completion Date
August 2010 (Actual)
Study Completion Date
August 2010 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Minnesota
Collaborators
National Institute on Drug Abuse (NIDA)

4. Oversight

5. Study Description

Brief Summary
Smokers report that they often smoke cigarettes during stressful times. The combined effect of smoking and exposure to stress leads to exaggerated increases in blood pressure, heart rate and other measures of stress response. This combination may result in greater cardiovascular harm than either smoking or stress alone. The purpose of this study is to determine the effects of paroxetine on the response to stress after smoking.
Detailed Description
Smokers report that they often smoke cigarettes during stressful times. Smoking and stress produce similar physiological responses such as increases in heart rate, blood pressure, and adrenaline levels. The combination of smoking and stress results in greater increases in these physiological responses compared to smoking or stress alone. Such increases are thought to be harmful to cardiovascular health. Additionally, smokers with exaggerated responses to stress may be more likely to relapse following a smoking cessation attempt. The purpose of this study is to assess the effects of paroxetine, a selective serotonin reuptake inhibitor (SSRI), on the cardiovascular response to stress after smoking. Participants in this double-blind, placebo-controlled study will receive 1 month of paroxetine and 1 month of placebo with the order of which is taken during the first month randomly assigned. Paroxetine will be administered at a daily dose of 10 mg for the first week and increased to a daily dose of 20 mg for the remainder of the study. After one month of medication, participants will abstain from smoking for one night and then undergo mental stress testing the following day. Immediately prior to the mental stress testing, participants will smoke a cigarette. Mental stressors will include speaking and math tasks. Physiological measures of stress (e.g., blood pressure, heart rate, and plasma catecholamine concentrations) and subjective measures of stress will be evaluated. Following the second month of medication, participants will again undergo the procedure for mental stress testing and evaluation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Tobacco Use Disorder
Keywords
Smoking

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
105 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
Active medication for 4 weeks followed by placebo for 4 weeks
Arm Title
2
Arm Type
Experimental
Arm Description
Placebo for 4 weeks followed by active for 4 weeks
Intervention Type
Drug
Intervention Name(s)
Paroxetine
Intervention Description
10 mg for 1 week followed by 20 mg for 3 weeks
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Systolic Blood Pressure Response to Stress
Description
Change in systolic blood pressure from Resting period to that observed during a speech delivered immediately after smoking a cigarette
Time Frame
After 4 weeks of paroxetine / placebo
Other Pre-specified Outcome Measures:
Title
Diastolic Blood Pressure Response to Stress
Description
Change in diastolic blood pressure from Resting period to that observed during a speech delivered immediately after smoking a cigarette
Time Frame
After 4 weeks of paroxetine / placebo
Title
Heart Rate Response to Stress
Description
Change in heart rate from Resting period to that observed during a speech delivered immediately after smoking a cigarette
Time Frame
After 4 weeks of paroxetine / placebo
Title
Plasma Epinephrine Concentration Response to Stress
Description
Change in plasma epinephrine concentrations from Resting period to those observed during a speech delivered immediately after smoking a cigarette
Time Frame
After 4 weeks of paroxetine / placebo
Title
Plasma Norepinephrine Concentration Response to Stress
Description
Change in plasma norepinephrine concentrations from Resting period to those observed during a speech delivered immediately after smoking a cigarette
Time Frame
After 4 weeks of paroxetine / placebo

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Smokes an average of at least 10 cigarettes per day during the year prior to enrollment Exclusion Criteria: Interested in quitting smoking within the 3 months following enrollment Current unstable medical condition Substance abuse within the year prior to enrollment Current use of any medications (e.g., psychoactive medications, antihypertensives) that, in the opinion of the investigators, might interfere with study measures or that would be expected to interact with paroxetine (e.g., CYP2D6 substrates) Smoking cessation therapy within the 3 months prior to enrollment Regular use of any form of tobacco other than cigarettes Significant psychiatric disorders as assessed by the PRIME-MD and verified by a clinician History of hypersensitivity to any selective serotonin reuptake inhibitor Pregnancy or breastfeeding
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Kotlyar
Organizational Affiliation
University of Minnesota
Official's Role
Principal Investigator
Facility Information:
Facility Name
College of Pharmacy
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55455
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
23504241
Citation
Kotlyar M, al'Absi M, Thuras P, Vuchetich JP, Adson DE, Nowack AL, Hatsukami DK. Effect of paroxetine on physiological response to stress and smoking. Psychosom Med. 2013 Apr;75(3):236-43. doi: 10.1097/PSY.0b013e3182898f6d. Epub 2013 Mar 15.
Results Reference
derived

Learn more about this trial

Effect of Paroxetine on Smokers' Cardiovascular Response to Stress - 1

We'll reach out to this number within 24 hrs